KARD (Kardigan) Other Operating Expense: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KARD Kardigan Inc KARD
11 GF Score
Price $20.49
! 1 Warning Sign
View Full Analysis

What is Kardigan Other Operating Expense?

Kardigan KARD +3.13% 11 Other Operating Expense is $ Mil as of Dec. 2025. GuruFocus rates KARD with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Kardigan's Other Operating Expense for the six months ended in Dec. 2025 was $0.00 Mil. Kardigan does not have enough years/quarters to calculate its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025.

Kardigan's quarterly Other Operating Expense increased from . 20 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Kardigan's annual Other Operating Expense increased from . 20 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Kardigan Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Kardigan's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kardigan Other Operating Expense Chart

Kardigan Annual Data
Trend Dec24 Dec25
Other Operating Expense
0.00 0.00

Kardigan Semi-Annual Data
Dec24 Dec25
Other Operating Expense 0.00 0.00
KARD
11GF Score
Kardigan Inc KARD
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kardigan Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $ Mil mean?
Kardigan (KARD) has a Other Operating Expense of $ Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Kardigan and its competitors.
Is Kardigan's Other Operating Expense too high?
Kardigan's current Other Operating Expense is $ Mil. Overall, Kardigan has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kardigan's Other Operating Expense compare to OCUL and GHRS?
Kardigan's Other Operating Expense of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Kardigan and its competitors. Kardigan's current Other Operating Expense is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kardigan stock overvalued right now?
Kardigan (KARD) has a current Other Operating Expense of $ Mil. The current Other Operating Expense is $ Mil. Kardigan's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Kardigan (KARD), the current Other Operating Expense is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kardigan Business Description

Address 506 Carnegie Center Drive, Suite 201, Princeton, NJ, USA, 08540
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
11GF Score

Get the complete analysis for KARD

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.49
Price